EVOQUE Tricuspid Valve Replacement System
Edwards Lifesciences, LLC · Decision date Oct 21, 2026
What did the FDA approve?
The FDA record for P230013/S033, decided October 21, 2026, is a real-time process supplement to the original PMA for the EVOQUE Tricuspid Valve Replacement System. The listed reason is a change to design, components, specifications or material, and the stated purpose is approval of design changes to the guide pin components used in the delivery system. That scope covers delivery-system hardware, not the valve prosthesis itself.
The P230013 identifier ties this action to the parent approval, but a supplement is not a new approval of the whole system, and this entry is not an original PMA. The source reports an approval for changed guide pin components; it does not state what the changes were, why they were made, or what testing supported them. It contains no clinical or performance data, so the decision shows the change was cleared as described, not that safety or effectiveness was independently demonstrated.
The filing text gives no details on guide pin dimensions, materials, compatibility or affected lots; those specifics are absent.
FDA approval order statement
Approval for design changes to the guide pin components used in the delivery system
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 21, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P230013/S033
- Regulatory pathway
- PMA supplement
- Applicant
- Edwards Lifesciences, LLC
- Product code
- NPW
- Decision code
- APPR
- Decision date
- Oct 21, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Percutaneously Delivered Prostheses and Tricuspid Valves.
- Applicant
- Edwards Lifesciences, LLC
- Product code
- NPW
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230013. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230013 · Original PMA
Edwards EVOQUE Tricuspid Valve Replacement System
P230013/S033 received
Application receipt date recorded by FDA.
P230013/S027 · Related supplement
EVOQUE Tricuspid Valve Replacement System
P230013/S029 · Related supplement
Edwards EVOQUE Tricuspid Valve Replacement System
P230013/S033 · FDA decision
Real-Time Process
P230013/S034 · Related supplement
Edwards EVOQUE Tricuspid Valve Replacement System (9850EV)
Timeline entries are records held by MedtechLedger for P230013. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230013
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Edwards Lifesciences, LLC | PMA approval | Feb 1, 2024 | FDA | |
EVOQUE Tricuspid Valve Replacement SystemP230013/S027 | Edwards Lifesciences, LLC | PMA supplement | Sep 16, 2026 | FDA |
| Edwards Lifesciences, LLC | PMA supplement | Oct 19, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 28, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Edwards Lifesciences, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- One Edwards Way, Irvine, CA, 92614
Sources and methodology
- Original FDA record: P230013/S033
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records